Introduction:
FUJIFILM Diosynth Biotechnologies plans for the construction of largest cell culture biophramaceutical CDMO facility. The facility will be located in North America.
Features:
The new, state-of-the-art facility consists of large-scale cell culture manufacturing of bulk drug substance production with 8 x 20,000L bioreactors.
This facility having the potential to expand will add further 24 x 20,000L bioreactors. Moreover, it expands and further add 24 x 20,000L bioreactors.
The new biopharmaceutical facility also consists of automated fill-finish, commercial-scale, packaging and labelling services. In addition, the new facility will have the ability to produce life-impacting medicines.
The new facility is expected to be completed and fully opeartional by spring 2025. Once the construction is completed it is expected to create 725 new jobs.
Specifications:
| Name | FUJIFILM Diosynth Biotechnologies |
| Type | New Construction |
| Year | 2025 |
